PFE logo

PFIZER INC

PFENYSE
πŸ† #93 by market capEarnings Nov 3US Equity
$28.30β–Ό $0.42 (βˆ’1.47%)
Live
πŸ””
Track PFE
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.5%
7dβ–² 1.3%
14dβ–² 2.7%
30dβ–² 1.2%
ytdβ–² 13.6%
1yβ–² 18.6%
🏦Market Cap
$161.28B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-0.2%
Declining
πŸ“ŠGross Margin
74.7%
High
πŸ’΅FCF Margin
17.2%
Healthy
βš–οΈP/S Ratio
2.6x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$28.12 – $28.54
52-Week Range
$23.58 – $29.21
Volume
$4.59B
Avg Volume
$5.16B
Shares Outstanding
5.70B
Next Earnings
Nov 7, 2026

Fundamentals Snapshot

Annual Revenue
$62.58B
Last Q Revenue
$15.03B
P/E Ratio
37.7
P/S Ratio
2.6x
EPS (TTM)
$0.76
Dividend Yield
5.99%
Dilution (1yr)
βˆ’0.3%

Why Investors Own PFE

  • βœ“High-growth profile β€” revenue up +45.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 28% gross margin and 24% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PFE logo

PFIZER INC

PFE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$62.6Bβ–Ό βˆ’1.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.3%β–² +6.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$15.4Bβ–Ό βˆ’6.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$9.1Bβ–Ό βˆ’7.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
5.69Bβ–Ό βˆ’0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$66.3Bβ–Ό βˆ’$3.7B YoY
StockOtter Β· stockotter.space

About PFIZER INC

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Price Target

β“˜
Average Target
$27.20
β–Ό βˆ’3.9% Downside
High Target$32.61
Low Target$22.09
Based on 30 analysts

Latest News & Updates

πŸš€
Zacks Investment ResearchΒ·5h ago

Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?

NVO and PFE offer different growth paths, with diversified portfolios, pipelines and near-term challenges shaping their outlooks.

GlobeNewsWireΒ·9h ago

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein deg

Seeking AlphaΒ·14h ago

Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough

Pfizer is rated a Buy, with a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. PFE's new and acquired products are delivering strong double-digit growth, helping offset lo

πŸš€
Zacks Investment ResearchΒ·1d ago

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Business WireΒ·1d ago

Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, t

Seeking AlphaΒ·3d ago

Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogs

Long-term bond yields persist despite pressure and circular remedies. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. β€œ23 stocks pa